Olumiant (Baricitinib)

Baricitinib, the active ingredient in Olumiant, is a Janus kinase (JAK) inhibitor presented as a tablet for oral use. It is indicated for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more disease‑modifying antirheumatic drugs. GNH USA supplies Olumiant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olumiant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olumiant is a Janus kinase inhibitor used in several inflammatory and autoimmune disease pathways.

- Rheumatoid arthritis: reduces signs and symptoms, and slows radiographic progression of disease. - COVID‑19 pneumonia (hospitalised): improves clinical outcomes by reducing the need for mechanical ventilation. - Atopic dermatitis: allevi of moderate to severe skin inflammation when topical therapies have failed. - Alopecia universe un un un un un un un un un un un un un un un un un un un

Barumi...

...

...